Clinical Trial Update: Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ruxolitinib with a de-intensified HLH-94 regimen for Hemophagocytic Lymphohistiocytosis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Jerry Lee, MD, MSc, MPhil | Conditions: Hemophagocytic Lymphohistiocytoses | Phase 2 | Status: RECRUITING